Production (Stage)
ACADIA Pharmaceuticals Inc.
ACAD
$21.98
$0.432.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.70% | 12.36% | 18.28% | 46.44% | 73.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.70% | 12.36% | 18.28% | 46.44% | 73.75% |
| Cost of Revenue | 19.40% | 44.78% | -50.19% | 42.63% | 16.69% |
| Gross Profit | 18.23% | -6.38% | 311.17% | 48.98% | 158.55% |
| SG&A Expenses | 17.02% | 16.70% | 20.95% | 21.98% | 6.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.05% | 28.82% | -24.35% | 30.41% | 10.80% |
| Operating Income | 26.82% | -80.00% | 180.56% | 902.21% | 128.39% |
| Income Before Tax | 32.27% | 305.73% | 174.42% | 486.19% | 146.73% |
| Income Tax Expenses | 97.71% | 384.59% | -53.65% | -27.46% | 331.86% |
| Earnings from Continuing Operations | 14.69% | 213.87% | 150.27% | 2,897.22% | 138.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.69% | 213.87% | 150.27% | 2,897.22% | 138.48% |
| EBIT | 26.82% | -80.00% | 180.56% | 902.21% | 128.39% |
| EBITDA | 7.25% | -66.64% | 187.62% | 587.24% | 139.01% |
| EPS Basic | 13.23% | 210.58% | 149.75% | 2,866.18% | 137.91% |
| Normalized Basic EPS | 30.61% | -58.31% | 201.92% | 477.78% | 146.04% |
| EPS Diluted | 10.00% | 213.27% | 149.35% | 2,841.18% | 137.04% |
| Normalized Diluted EPS | 31.35% | -57.94% | 201.81% | 482.50% | 145.52% |
| Average Basic Shares Outstanding | 1.22% | 1.05% | 1.06% | 1.28% | 1.56% |
| Average Diluted Shares Outstanding | 0.63% | 0.11% | 1.18% | 0.68% | 2.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |